1)Schweitzer PK, Taranto-Montemurro L, Ojile JM, Thein SG, Drake CL, et al: The combination of aroxybutynin and atomoxetine in the treatment of obstructive sleep apnea (MARIPOSA): a randomized controlled trial. Am J Respir Crit Care Med 208: 1316-1327, 2023
2)Apnimed: Apnimed announces positive topline results in the first landmark phase 3 clinical trial of AD109, an investigational once-daily oral pill for obstructive sleep apnea. https://apnimed.com/article/ad109phase3toplineresults/(最終閲覧日: 2025年8月21日)
3)Ueki Y, Hayashida K, Komada Y, Nakamura M, Kobayashi M, et al: Factors associated with duration before receiving definitive diagnosis of narcolepsy among Japanese patients affected with the disorder. Int J Behaw Med 21: 966-970, 2014
4)Dauvilliers Y, Plazzi G, Mignot E, Lammers GJ, Del Río Villegas R, et al: Oveporexton, an oral orexin receptor 2-selective agonist, in narcolepsy Type 1. N Engl J Med 392: 1905-1916, 2025
5)Evans R, Kimura H, Alexander R, Davies CH, Faessel H, et al: Orexin 2 receptor-selective agonist danavorexton improves narcolepsy phenotype in a mouse model and in human patients. Proc Natl Acad Sci U S A 119: e2207531119, 2022[doi: 10.1073/pnas.2207531119]